United States - English - NLM (National Library of Medicine)

generamedix inc. - melphalan hydrochloride (unii: 1vxp4v453t) (melphalan - unii:q41or9510p) - melphalan hydrochloride 50 mg in 10 ml - melphalan hydrochloride for injection is indicated for the palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate. melphalan should not be used in patients whose disease has demonstrated prior resistance to this agent. patients who have demonstrated hypersensitivity to melphalan should not be given the drug.

United States - English - NLM (National Library of Medicine)

mylan institutional llc - melphalan hydrochloride (unii: 1vxp4v453t) (melphalan - unii:q41or9510p) - melphalan 50 mg in 10 ml - melphalan hydrochloride for injection is indicated for the palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate. melphalan should not be used in patients whose disease has demonstrated prior resistance to this agent. patients who have demonstrated hypersensitivity to melphalan should not be given the drug.

United States - English - NLM (National Library of Medicine)

par pharmaceutical, inc. - melphalan (unii: q41or9510p) (melphalan - unii:q41or9510p) - melphalan 50 mg in 10 ml - melphalan hydrochloride for injection is indicated for the palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate. melphalan should not be used in patients whose disease has demonstrated prior resistance to this agent. patients who have demonstrated hypersensitivity to melphalan should not be given the drug.

United States - English - NLM (National Library of Medicine)

actavis pharma, inc. - melphalan hydrochloride (unii: 1vxp4v453t) (melphalan - unii:q41or9510p) - melphalan 50 mg in 10 ml - melphalan hydrochloride for injection is indicated for the palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate. melphalan hydrochloride for injection should not be used in patients whose disease has demonstrated prior resistance to this agent. patients who have demonstrated hypersensitivity to melphalan should not be given the drug.

United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - melphalan hydrochloride (unii: 1vxp4v453t) (melphalan - unii:q41or9510p) - melphalan 50 mg in 10 ml - melphalan hydrochloride for injection is indicated for the palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate. melphalan should not be used in patients whose disease has demonstrated prior resistance to this agent.  patients who have demonstrated hypersensitivity to melphalan should not be given the drug.

United States - English - NLM (National Library of Medicine)

alvogen inc. - melphalan (unii: q41or9510p) (melphalan - unii:q41or9510p) - melphalan 2 mg - melphalan tablets usp are indicated for the palliative treatment of multiple myeloma and for the palliation of non-resectable epithelial carcinoma of the ovary. melphalan tablets usp should not be used in patients whose disease has demonstrated a prior resistance to this agent. patients who have demonstrated hypersensitivity to melphalan should not be given the drug.

United States - English - NLM (National Library of Medicine)

dr.reddy's laboratories inc - melphalan hydrochloride (unii: 1vxp4v453t) (melphalan - unii:q41or9510p) - melphalan 50 mg in 10 ml - melphalan hydrochloride for injection is indicated for the palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate. melphalan hydrochloride for injection should not be used in patients whose disease has demonstrated prior resistance to this agent. patients who have demonstrated hypersensitivity to melphalan hydrochloride for injection should not be given the drug.

United States - English - NLM (National Library of Medicine)

sagent pharmaceuticals - melphalan hydrochloride (unii: 1vxp4v453t) (melphalan - unii:q41or9510p) - melphalan 50 mg in 10 ml - melphalan hydrochloride for injection is indicated for the palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate. melphalan should not be used in patients whose disease has demonstrated prior resistance to this agent. patients who have demonstrated hypersensitivity to melphalan should not be given the drug.

Israel - English - Ministry of Health

raz pharmaceutics ltd, israel - melphalan as hydrochloride - powder and solvent for solution for injection/infusion - melphalan as hydrochloride 50 mg - melphalan - for the palliative treatment of multiple myeloma and for the palliation of non resectable epithelial cancer of the ovary.

Ireland - English - HPRA (Health Products Regulatory Authority)

teva b.v. - melphalan - pdr+solv for soln for inf/inj - 50 milligram - melphalan